Antígeno prostático específico y factores de riesgo asociados a anomalías prostáticas
Palabras clave:
Cáncer de próstata; Diagnóstico; Hiperplasia prostática benigna; Frecuencia; Factores predisponentes.
Resumen
Estudios previos describen que el antígeno prostático específico y el tamaño de la próstata es tan alta y positivamente correlacionados, pero no existe un consenso sobre la utilidad, especialmente porque los factores de riesgo son múltiples y controversiales. El objetivo del estudio fue analizar evidencias científicas sobre el antígeno prostático específico y los factores de riesgo asociado a anomalías prostáticas. La investigación de diseño documental tipo descriptivo, permitió seleccionar desde bases de datos científicas, en inglés y español, artículos relacionados al tema publicados entre los años 2018 a 2022, además de utilizar palabras claves concernientes al tema de estudio. En los criterios de inclusión se incluyeron artículos a texto completo, de revisión, originales, metaanálisis, reportes de caso, textos digitales de divulgación científica del último año y páginas oficiales de salud relacionadas al tema. Por lo que la evidencia actualmente disponible sugiere que el antígeno prostático específico es altamente sensible, pero poco específico para la detección del cáncer de próstata y su diferenciación de otras anomalías especialmente las benignas.
Descargas
La descarga de datos todavía no está disponible.
Citas
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
2. Chandra Engel, J., Palsdottir, T., Aly, M., Egevad, L., Grönberg, H., Eklund, M., & Nordström, T. (2020). Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≥3 ng/ml. Scandinavian Journal of Urology, 54(1), 1-6. https://doi.org/10.1080/21681805.2019.1703806
3. Chen, P.-Y., Chen, S.-M., Juang, H.-H., Hou, C.-P., Lin, Y.-H., Yang, P.-S., Chen, C.-L., Chang, P.-L., Lin, K.-Y., & Tsui, K.-H. (2021). Prostate-Specific Antigen Velocity Predicts Surgical Outcome of Thulium Laser Enucleation of the Prostate. Frontiers in Medicine, 8, 783221. https://doi.org/10.3389/fmed.2021.783221
4. Cifras de Ecuador – Cáncer de Mama – Ministerio de Salud Pública. (s. f.). Recuperado 26 de octubre de 2022, de https://www.salud.gob.ec/cifras-de-ecuador-cancer-de-mama/
5. Crawley, D., Chamberlain, F., Garmo, H., Rudman, S., Zethelius, B., Holmberg, L., Adolfsson, J., Stattin, P., Carroll, P., & Van Hemerijck, M. (2018). A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. ecancermedicalscience, 12. https://doi.org/10.3332/ecancer.2018.802
6. Ehlers, S., & Merrill, S. A. (2022). Staphylococcus Saprophyticus. En StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK482367/
7. Ene, C.-V., Nicolae, I., Geavlete, B., Geavlete, P., & Ene, C. D. (2022). IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis. Analytical Cellular Pathology, 2022, 1-10. https://doi.org/10.1155/2022/5980387
8. Estadísticas—Incidencia. (2019, febrero 17). Argentina.gob.ar. https://www.argentina.gob.ar/salud/instituto-nacional-del-cancer/estadisticas/incidencia
9. Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018a). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 103, 356-387. https://doi.org/10.1016/j.ejca.2018.07.005
10. Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018b). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 103, 356-387. https://doi.org/10.1016/j.ejca.2018.07.005
11. Ferraro, S., Bussetti, M., Bassani, N., Rossi, R. S., Incarbone, G. P., Bianchi, F., Maggioni, M., Runza, L., Ceriotti, F., & Panteghini, M. (2021). Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers, 13(14), 3381. https://doi.org/10.3390/cancers13143381
12. Freedland, A. R., Muller, R. L., Hoyo, C., Turner, E. L., Moorman, P. G., Faria, E. F., Carvalhal, G. F., Reis, R. B., Mauad, E. C., Carvalho, A. L., & Freedland, S. J. (2021a). Implications of Regionalizing Care in the Developing World: Impact of Distance to Referral Center on Compliance to Biopsy Recommendations in a Brazilian Prostate Cancer Screening Cohort. Prostate Cancer, 2021, 1-8. https://doi.org/10.1155/2021/6614838
13. Freedland, A. R., Muller, R. L., Hoyo, C., Turner, E. L., Moorman, P. G., Faria, E. F., Carvalhal, G. F., Reis, R. B., Mauad, E. C., Carvalho, A. L., & Freedland, S. J. (2021b). Implications of Regionalizing Care in the Developing World: Impact of Distance to Referral Center on Compliance to Biopsy Recommendations in a Brazilian Prostate Cancer Screening Cohort. Prostate Cancer, 2021, 1-8. https://doi.org/10.1155/2021/6614838
14. Gao, X., Li, R., Jin, T., & Tang, H. (2022). The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese. Frontiers in Endocrinology, 13, 787268. https://doi.org/10.3389/fendo.2022.787268
15. Gao, X.-D., Miao, Q., Zhang, J.-L., Zhai, J.-Z., Gui, X.-M., Cai, Y.-H., Niu, Q., & Cai, B. (2022). Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml -1 in Western China. Asian Journal of Andrology, 24(2), 195. https://doi.org/10.4103/aja202182
16. Gaver, A. (2022). Too Much Healthcare: The Harmful Combination of Overdiagnosis and Medical Overuse, Told and Untold Stories. The Israel Medical Association Journal: IMAJ, 24(6), 399-402.
17. Han, C., Zhu, L., Liu, X., Ma, S., Liu, Y., & Wang, X. (2021). Differential diagnosis of uncommon prostate diseases: Combining mpMRI and clinical information. Insights into Imaging, 12(1), 79. https://doi.org/10.1186/s13244-021-01024-3
18. Harrison, S., Tilling, K., Turner, E. L., Martin, R. M., Lennon, R., Lane, J. A., Donovan, J. L., Hamdy, F. C., Neal, D. E., Bosch, J. L. H. R., & Jones, H. E. (2020). Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes & Control, 31(5), 431-449. https://doi.org/10.1007/s10552-020-01291-3
19. Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ, k3519. https://doi.org/10.1136/bmj.k3519
20. Jin, Y., Jung, J. H., Han, W. K., Hwang, E. C., Nho, Y., Lee, N., Yun, J. E., Lee, K. S., Lee, S. H., Lee, H., & Yu, S.-Y. (2022). Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis. Investigative and Clinical Urology, 63(3), 251-261. https://doi.org/10.4111/icu.20210429
21. Kang, D.-W., Fairey, A. S., Boulé, N. G., Field, C. J., Wharton, S. A., & Courneya, K. S. (2021). Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial. JAMA Oncology, 7(10), 1487. https://doi.org/10.1001/jamaoncol.2021.3067
22. Kim, J. Y., Yu, J. H., Sung, L. H., Cho, D. Y., Kim, H.-J., & Yoo, S. J. (2021). Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: A prospective observational study. BMC Urology, 21(1), 131. https://doi.org/10.1186/s12894-021-00897-2
23. Lagacé, F., Ghazawi, F. M., Le, M., Savin, E., Zubarev, A., Powell, M., Moreau, L., Sasseville, D., Popa, I., & Litvinov, I. V. (2021). Incidence and Mortality of Prostate Cancer in Canada during 1992–2010. Current Oncology, 28(1), 978-990. https://doi.org/10.3390/curroncol28010096
24. Lan, S., Guo, Z., He, Y., Liu, W., & Guo, H. (2021). Brucella prostatic abscess: A retrospective study of eight cases and a literature review. Journal of International Medical Research, 49(9), 030006052110274. https://doi.org/10.1177/03000605211027442
25. Li, Q. K., Chen, J., Hu, Y., Höti, N., Lih, T.-S. M., Thomas, S. N., Chen, L., Roy, S., Meeker, A., Shah, P., Chen, L., Bova, G. S., Zhang, B., & Zhang, H. (2021). Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Scientific Reports, 11(1), 18936. https://doi.org/10.1038/s41598-021-98410-0
26. Li, Z., Wen, J., & Zhang, N. (2020). Emphysematous prostatic abscess due to candidiasis: A case report and review of the literature. Medicine, 99(9), e19391. https://doi.org/10.1097/MD.0000000000019391
27. Loloi, J., Wei, M., Babar, M., Zhu, D., Fram, E. B., & Maria, P. (2022). Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative. International Braz j Urol, 48, 688-695. https://doi.org/10.1590/S1677-5538.IBJU.2022.0099
28. Lundgren, P.-O., Kjellman, A., Norming, U., & Gustafsson, O. (2018). Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. Journal of Urology, 200(1), 82-88. https://doi.org/10.1016/j.juro.2018.01.080
29. Madersbacher, S., Sampson, N., & Culig, Z. (2019). Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 65(5), 458-464. https://doi.org/10.1159/000496289
30. Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E. E., Jamialahmadi, T., & Sahebkar, A. (2021). PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy, 140, 111758. https://doi.org/10.1016/j.biopha.2021.111758
31. Makdissi, F. B. A., Santos, S. S., Bitencourt, A., & Campos, F. A. B. (2022). An introduction to male breast cancer for urologists: Epidemiology, diagnosis, principles of treatment, and special situations. International Braz j Urol, 48, 760-770. https://doi.org/10.1590/S1677-5538.IBJU.2021.0828
32. Morka, N., Norris, J. M., Emberton, M., & Kelly, D. (2022). Prostate cancer and the human papilloma virus: Causative association, role of vaccines, and the impact of the COVID-19 pandemic. Prostate Cancer and Prostatic Diseases, 25(1), 55-57. https://doi.org/10.1038/s41391-021-00404-6
33. Nordström, T., Engel, J. C., Bergman, M., Egevad, L., Aly, M., Eklund, M., Palsdottir, T., & Grönberg, H. (2021). Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 24, 11-16. https://doi.org/10.1016/j.euros.2020.12.004
34. Nyame, Y. A., Gulati, R., Heijnsdijk, E. A. M., Tsodikov, A., Mariotto, A. B., Gore, J. L., & Etzioni, R. (2021). The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. JNCI: Journal of the National Cancer Institute, 113(10), 1336-1342. https://doi.org/10.1093/jnci/djab072
35. on behalf of BPSC investigators, Zi, H., Wang, X.-J., Zhao, M.-J., Huang, Q., Wang, X.-H., & Zeng, X.-T. (2019). Fasting blood glucose level and hypertension risk in aging benign prostatic hyperplasia patients. Aging, 11(13), 4438-4445. https://doi.org/10.18632/aging.102061
36. Otifi, H. M., Abdul-Wahab, O. M. S., Al-Shyarba, M. H., Al Fayi, M. S. S., Al Murea, A. H., & Yacoub, E. (2022a). Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia. Saudi Medical Journal, 43(7), 755-759. https://doi.org/10.15537/smj.2022.43.7.20210758
37. Otifi, H. M., Abdul-Wahab, O. M. S., Al-Shyarba, M. H., Al Fayi, M. S. S., Al Murea, A. H., & Yacoub, E. (2022b). Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia. Saudi Medical Journal, 43(7), 755-759. https://doi.org/10.15537/smj.2022.43.7.20210758
38. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, n71. https://doi.org/10.1136/bmj.n71
39. Pepe, P., Pepe, L., Curdman, M., Pennisi, M., & Fraggetta, F. (2020). Primitive small cell carcinoma of the prostate. Case report and revision of the literature. Archivio Italiano di Urologia e Andrologia, 92(4). https://doi.org/10.4081/aiua.2020.4.390
40. Reis, R. B. dos, Alías-Melgar, A., Martínez-Cornelio, A., Neciosup, S. P., Sade, J. P., Santos, M., & Villoldo, G. M. (2020). Prostate Cancer in Latin America: Challenges and Recommendations. Cancer Control, 27(1), 107327482091572. https://doi.org/10.1177/1073274820915720
41. Salako, A., Badmus, T., Komolafe, A., David, R., Igbokwe, M., Laoye, A., Akinbola, I., Babalola, R., & Onyeze, C. (2019). Unusual presentation of advanced prostate cancer in a black population of South-Western Nigeria. Pan African Medical Journal, 32. https://doi.org/10.11604/pamj.2019.32.15.14417
42. Santos, M. de O. (2018). Estimativa 2018: Incidência de Câncer no Brasil. Revista Brasileira de Cancerologia, 64(1), Art. 1. https://doi.org/10.32635/2176-9745.RBC.2018v64n1.115
43. Siegel, D. A., O’Neil, M. E., Richards, T. B., Dowling, N. F., & Weir, H. K. (2020). Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity—United States, 2001-2017. MMWR. Morbidity and Mortality Weekly Report, 69(41), 1473-1480. https://doi.org/10.15585/mmwr.mm6941a1
44. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7-33. https://doi.org/10.3322/caac.21654
45. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33. https://doi.org/10.3322/caac.21708
46. Song, Z.-J., Qian, J.-K., Yang, Y., Wu, H.-X., Wang, M.-Y., Jiang, S.-Y., Wang, F.-B., Zhang, W., Chen, R., & Chinese Prostate Cancer Consortium, N. (2021a). PSA density in the diagnosis of prostate cancer in the Chinese population: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Andrology, 23(3), 300. https://doi.org/10.4103/aja.aja_61_20
47. Song, Z.-J., Qian, J.-K., Yang, Y., Wu, H.-X., Wang, M.-Y., Jiang, S.-Y., Wang, F.-B., Zhang, W., Chen, R., & Chinese Prostate Cancer Consortium, N. (2021b). PSA density in the diagnosis of prostate cancer in the Chinese population: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Andrology, 23(3), 300. https://doi.org/10.4103/aja.aja_61_20
48. Storebjerg, T. M., Strand, S. H., Høyer, S., Lynnerup, A.-S., Borre, M., Ørntoft, T. F., & Sørensen, K. D. (2018). Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clinical Epigenetics, 10(1), 105. https://doi.org/10.1186/s13148-018-0540-x
49. Sugimura, R., Kawahara, T., Noguchi, G., Takamoto, D., Izumi, K., Miyoshi, Y., Kishida, T., Yao, M., Tanabe, M., & Uemura, H. (2019). Clear cell adenocarcinoma of the prostatic urethra: A case report. IJU Case Reports, 2(1), 19-22. https://doi.org/10.1002/iju5.12028
50. Tapsoba, A. K., Rahoui, M., Bibi, M., Chelly, B., Ouanes, Y., Chaker, K., Dali, K. M., Sellami, A., Rhouma, S. B., & Nouira, Y. (2021). An unusual association of adenocarcinoma and isolated tuberculosis of prostate gland. Journal of Surgical Case Reports, 2021(11), rjab504. https://doi.org/10.1093/jscr/rjab504
51. The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate—PubMed. (s. f.). Recuperado 26 de octubre de 2022, de https://pubmed.ncbi.nlm.nih.gov/31487219/
52. Van Cauwenbergh, O., Di Serafino, A., Tytgat, J., & Soubry, A. (2020). Transgenerational epigenetic effects from male exposure to endocrine-disrupting compounds: A systematic review on research in mammals. Clinical Epigenetics, 12(1), 65. https://doi.org/10.1186/s13148-020-00845-1
53. Watts, E. L., Goldacre, R., Key, T. J., Allen, N. E., Travis, R. C., & Perez‐Cornago, A. (2020). Hormone‐related diseases and prostate cancer: An English national record linkage study. International Journal of Cancer, 147(3), 803-810. https://doi.org/10.1002/ijc.32808
54. Wu, W., Wang, L., Spetsieris, N., Boukovala, M., Efstathiou, E., Brössner, C., Warner, M., & Gustafsson, J.-A. (2021). Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proceedings of the National Academy of Sciences, 118(13), e2011269118. https://doi.org/10.1073/pnas.2011269118
55. Wu, Y., Ding, Y., Cao, Q. F., Qian, S. B., Wang, C., Duan, H. Q., Gu, J., & Shen, H. B. (2020). The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. World Journal of Urology, 38(11), 2923-2931. https://doi.org/10.1007/s00345-020-03084-4
56. Xia, B., Zhao, S., Chen, Z., Chen, C., Liu, T., Yang, F., & Yan, Y. (2020). The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. The Prostate, 80(6), 481-490. https://doi.org/10.1002/pros.23962
57. Xin, C., Fan, H., Xie, J., Hu, J., Sun, X., & Liu, Q. (2022). Impact of Diabetes Mellitus on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: A Meta-Analysis. Frontiers in Endocrinology, 12, 741748. https://doi.org/10.3389/fendo.2021.741748
58. Xiong, Y., Zhang, Y.-C., Jin, T., Qin, F., & Yuan, J.-H. (2021). Depressive males have higher odds of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A retrospective cohort study based on propensity score matching. Asian Journal of Andrology, 23(6), 633. https://doi.org/10.4103/aja.aja_12_21
59. Zhang, P., Qian, B., Liu, Z., Wang, D., Lv, F., Xing, Y., & Xiao, Y. (2021). Identification of novel biomarkers of prostate cancer through integrated analysis. Translational Andrology and Urology, 10(8), 3239-3254. https://doi.org/10.21037/tau-21-401
60. Zhou, Y., Xie, S., Zheng, R., Dai, Q., Xu, Z., Zuo, W., Ding, J., & Zhang, Y. (2020). Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. Journal of International Medical Research, 48(6), 030006052092454. https://doi.org/10.1177/0300060520924548
2. Chandra Engel, J., Palsdottir, T., Aly, M., Egevad, L., Grönberg, H., Eklund, M., & Nordström, T. (2020). Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≥3 ng/ml. Scandinavian Journal of Urology, 54(1), 1-6. https://doi.org/10.1080/21681805.2019.1703806
3. Chen, P.-Y., Chen, S.-M., Juang, H.-H., Hou, C.-P., Lin, Y.-H., Yang, P.-S., Chen, C.-L., Chang, P.-L., Lin, K.-Y., & Tsui, K.-H. (2021). Prostate-Specific Antigen Velocity Predicts Surgical Outcome of Thulium Laser Enucleation of the Prostate. Frontiers in Medicine, 8, 783221. https://doi.org/10.3389/fmed.2021.783221
4. Cifras de Ecuador – Cáncer de Mama – Ministerio de Salud Pública. (s. f.). Recuperado 26 de octubre de 2022, de https://www.salud.gob.ec/cifras-de-ecuador-cancer-de-mama/
5. Crawley, D., Chamberlain, F., Garmo, H., Rudman, S., Zethelius, B., Holmberg, L., Adolfsson, J., Stattin, P., Carroll, P., & Van Hemerijck, M. (2018). A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. ecancermedicalscience, 12. https://doi.org/10.3332/ecancer.2018.802
6. Ehlers, S., & Merrill, S. A. (2022). Staphylococcus Saprophyticus. En StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK482367/
7. Ene, C.-V., Nicolae, I., Geavlete, B., Geavlete, P., & Ene, C. D. (2022). IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis. Analytical Cellular Pathology, 2022, 1-10. https://doi.org/10.1155/2022/5980387
8. Estadísticas—Incidencia. (2019, febrero 17). Argentina.gob.ar. https://www.argentina.gob.ar/salud/instituto-nacional-del-cancer/estadisticas/incidencia
9. Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018a). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 103, 356-387. https://doi.org/10.1016/j.ejca.2018.07.005
10. Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018b). Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 103, 356-387. https://doi.org/10.1016/j.ejca.2018.07.005
11. Ferraro, S., Bussetti, M., Bassani, N., Rossi, R. S., Incarbone, G. P., Bianchi, F., Maggioni, M., Runza, L., Ceriotti, F., & Panteghini, M. (2021). Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. Cancers, 13(14), 3381. https://doi.org/10.3390/cancers13143381
12. Freedland, A. R., Muller, R. L., Hoyo, C., Turner, E. L., Moorman, P. G., Faria, E. F., Carvalhal, G. F., Reis, R. B., Mauad, E. C., Carvalho, A. L., & Freedland, S. J. (2021a). Implications of Regionalizing Care in the Developing World: Impact of Distance to Referral Center on Compliance to Biopsy Recommendations in a Brazilian Prostate Cancer Screening Cohort. Prostate Cancer, 2021, 1-8. https://doi.org/10.1155/2021/6614838
13. Freedland, A. R., Muller, R. L., Hoyo, C., Turner, E. L., Moorman, P. G., Faria, E. F., Carvalhal, G. F., Reis, R. B., Mauad, E. C., Carvalho, A. L., & Freedland, S. J. (2021b). Implications of Regionalizing Care in the Developing World: Impact of Distance to Referral Center on Compliance to Biopsy Recommendations in a Brazilian Prostate Cancer Screening Cohort. Prostate Cancer, 2021, 1-8. https://doi.org/10.1155/2021/6614838
14. Gao, X., Li, R., Jin, T., & Tang, H. (2022). The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese. Frontiers in Endocrinology, 13, 787268. https://doi.org/10.3389/fendo.2022.787268
15. Gao, X.-D., Miao, Q., Zhang, J.-L., Zhai, J.-Z., Gui, X.-M., Cai, Y.-H., Niu, Q., & Cai, B. (2022). Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml -1 in Western China. Asian Journal of Andrology, 24(2), 195. https://doi.org/10.4103/aja202182
16. Gaver, A. (2022). Too Much Healthcare: The Harmful Combination of Overdiagnosis and Medical Overuse, Told and Untold Stories. The Israel Medical Association Journal: IMAJ, 24(6), 399-402.
17. Han, C., Zhu, L., Liu, X., Ma, S., Liu, Y., & Wang, X. (2021). Differential diagnosis of uncommon prostate diseases: Combining mpMRI and clinical information. Insights into Imaging, 12(1), 79. https://doi.org/10.1186/s13244-021-01024-3
18. Harrison, S., Tilling, K., Turner, E. L., Martin, R. M., Lennon, R., Lane, J. A., Donovan, J. L., Hamdy, F. C., Neal, D. E., Bosch, J. L. H. R., & Jones, H. E. (2020). Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes & Control, 31(5), 431-449. https://doi.org/10.1007/s10552-020-01291-3
19. Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: A systematic review and meta-analysis. BMJ, k3519. https://doi.org/10.1136/bmj.k3519
20. Jin, Y., Jung, J. H., Han, W. K., Hwang, E. C., Nho, Y., Lee, N., Yun, J. E., Lee, K. S., Lee, S. H., Lee, H., & Yu, S.-Y. (2022). Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis. Investigative and Clinical Urology, 63(3), 251-261. https://doi.org/10.4111/icu.20210429
21. Kang, D.-W., Fairey, A. S., Boulé, N. G., Field, C. J., Wharton, S. A., & Courneya, K. S. (2021). Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial. JAMA Oncology, 7(10), 1487. https://doi.org/10.1001/jamaoncol.2021.3067
22. Kim, J. Y., Yu, J. H., Sung, L. H., Cho, D. Y., Kim, H.-J., & Yoo, S. J. (2021). Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: A prospective observational study. BMC Urology, 21(1), 131. https://doi.org/10.1186/s12894-021-00897-2
23. Lagacé, F., Ghazawi, F. M., Le, M., Savin, E., Zubarev, A., Powell, M., Moreau, L., Sasseville, D., Popa, I., & Litvinov, I. V. (2021). Incidence and Mortality of Prostate Cancer in Canada during 1992–2010. Current Oncology, 28(1), 978-990. https://doi.org/10.3390/curroncol28010096
24. Lan, S., Guo, Z., He, Y., Liu, W., & Guo, H. (2021). Brucella prostatic abscess: A retrospective study of eight cases and a literature review. Journal of International Medical Research, 49(9), 030006052110274. https://doi.org/10.1177/03000605211027442
25. Li, Q. K., Chen, J., Hu, Y., Höti, N., Lih, T.-S. M., Thomas, S. N., Chen, L., Roy, S., Meeker, A., Shah, P., Chen, L., Bova, G. S., Zhang, B., & Zhang, H. (2021). Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors. Scientific Reports, 11(1), 18936. https://doi.org/10.1038/s41598-021-98410-0
26. Li, Z., Wen, J., & Zhang, N. (2020). Emphysematous prostatic abscess due to candidiasis: A case report and review of the literature. Medicine, 99(9), e19391. https://doi.org/10.1097/MD.0000000000019391
27. Loloi, J., Wei, M., Babar, M., Zhu, D., Fram, E. B., & Maria, P. (2022). Rates of False-Negative Screening in Prostate Specific Antigen Secondary to 5-Alpha Reductase Inhibitor Usage: A Quality-Improvement Initiative. International Braz j Urol, 48, 688-695. https://doi.org/10.1590/S1677-5538.IBJU.2022.0099
28. Lundgren, P.-O., Kjellman, A., Norming, U., & Gustafsson, O. (2018). Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. Journal of Urology, 200(1), 82-88. https://doi.org/10.1016/j.juro.2018.01.080
29. Madersbacher, S., Sampson, N., & Culig, Z. (2019). Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 65(5), 458-464. https://doi.org/10.1159/000496289
30. Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E. E., Jamialahmadi, T., & Sahebkar, A. (2021). PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy, 140, 111758. https://doi.org/10.1016/j.biopha.2021.111758
31. Makdissi, F. B. A., Santos, S. S., Bitencourt, A., & Campos, F. A. B. (2022). An introduction to male breast cancer for urologists: Epidemiology, diagnosis, principles of treatment, and special situations. International Braz j Urol, 48, 760-770. https://doi.org/10.1590/S1677-5538.IBJU.2021.0828
32. Morka, N., Norris, J. M., Emberton, M., & Kelly, D. (2022). Prostate cancer and the human papilloma virus: Causative association, role of vaccines, and the impact of the COVID-19 pandemic. Prostate Cancer and Prostatic Diseases, 25(1), 55-57. https://doi.org/10.1038/s41391-021-00404-6
33. Nordström, T., Engel, J. C., Bergman, M., Egevad, L., Aly, M., Eklund, M., Palsdottir, T., & Grönberg, H. (2021). Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 24, 11-16. https://doi.org/10.1016/j.euros.2020.12.004
34. Nyame, Y. A., Gulati, R., Heijnsdijk, E. A. M., Tsodikov, A., Mariotto, A. B., Gore, J. L., & Etzioni, R. (2021). The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. JNCI: Journal of the National Cancer Institute, 113(10), 1336-1342. https://doi.org/10.1093/jnci/djab072
35. on behalf of BPSC investigators, Zi, H., Wang, X.-J., Zhao, M.-J., Huang, Q., Wang, X.-H., & Zeng, X.-T. (2019). Fasting blood glucose level and hypertension risk in aging benign prostatic hyperplasia patients. Aging, 11(13), 4438-4445. https://doi.org/10.18632/aging.102061
36. Otifi, H. M., Abdul-Wahab, O. M. S., Al-Shyarba, M. H., Al Fayi, M. S. S., Al Murea, A. H., & Yacoub, E. (2022a). Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia. Saudi Medical Journal, 43(7), 755-759. https://doi.org/10.15537/smj.2022.43.7.20210758
37. Otifi, H. M., Abdul-Wahab, O. M. S., Al-Shyarba, M. H., Al Fayi, M. S. S., Al Murea, A. H., & Yacoub, E. (2022b). Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia. Saudi Medical Journal, 43(7), 755-759. https://doi.org/10.15537/smj.2022.43.7.20210758
38. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, n71. https://doi.org/10.1136/bmj.n71
39. Pepe, P., Pepe, L., Curdman, M., Pennisi, M., & Fraggetta, F. (2020). Primitive small cell carcinoma of the prostate. Case report and revision of the literature. Archivio Italiano di Urologia e Andrologia, 92(4). https://doi.org/10.4081/aiua.2020.4.390
40. Reis, R. B. dos, Alías-Melgar, A., Martínez-Cornelio, A., Neciosup, S. P., Sade, J. P., Santos, M., & Villoldo, G. M. (2020). Prostate Cancer in Latin America: Challenges and Recommendations. Cancer Control, 27(1), 107327482091572. https://doi.org/10.1177/1073274820915720
41. Salako, A., Badmus, T., Komolafe, A., David, R., Igbokwe, M., Laoye, A., Akinbola, I., Babalola, R., & Onyeze, C. (2019). Unusual presentation of advanced prostate cancer in a black population of South-Western Nigeria. Pan African Medical Journal, 32. https://doi.org/10.11604/pamj.2019.32.15.14417
42. Santos, M. de O. (2018). Estimativa 2018: Incidência de Câncer no Brasil. Revista Brasileira de Cancerologia, 64(1), Art. 1. https://doi.org/10.32635/2176-9745.RBC.2018v64n1.115
43. Siegel, D. A., O’Neil, M. E., Richards, T. B., Dowling, N. F., & Weir, H. K. (2020). Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity—United States, 2001-2017. MMWR. Morbidity and Mortality Weekly Report, 69(41), 1473-1480. https://doi.org/10.15585/mmwr.mm6941a1
44. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7-33. https://doi.org/10.3322/caac.21654
45. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33. https://doi.org/10.3322/caac.21708
46. Song, Z.-J., Qian, J.-K., Yang, Y., Wu, H.-X., Wang, M.-Y., Jiang, S.-Y., Wang, F.-B., Zhang, W., Chen, R., & Chinese Prostate Cancer Consortium, N. (2021a). PSA density in the diagnosis of prostate cancer in the Chinese population: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Andrology, 23(3), 300. https://doi.org/10.4103/aja.aja_61_20
47. Song, Z.-J., Qian, J.-K., Yang, Y., Wu, H.-X., Wang, M.-Y., Jiang, S.-Y., Wang, F.-B., Zhang, W., Chen, R., & Chinese Prostate Cancer Consortium, N. (2021b). PSA density in the diagnosis of prostate cancer in the Chinese population: Results from the Chinese Prostate Cancer Consortium. Asian Journal of Andrology, 23(3), 300. https://doi.org/10.4103/aja.aja_61_20
48. Storebjerg, T. M., Strand, S. H., Høyer, S., Lynnerup, A.-S., Borre, M., Ørntoft, T. F., & Sørensen, K. D. (2018). Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clinical Epigenetics, 10(1), 105. https://doi.org/10.1186/s13148-018-0540-x
49. Sugimura, R., Kawahara, T., Noguchi, G., Takamoto, D., Izumi, K., Miyoshi, Y., Kishida, T., Yao, M., Tanabe, M., & Uemura, H. (2019). Clear cell adenocarcinoma of the prostatic urethra: A case report. IJU Case Reports, 2(1), 19-22. https://doi.org/10.1002/iju5.12028
50. Tapsoba, A. K., Rahoui, M., Bibi, M., Chelly, B., Ouanes, Y., Chaker, K., Dali, K. M., Sellami, A., Rhouma, S. B., & Nouira, Y. (2021). An unusual association of adenocarcinoma and isolated tuberculosis of prostate gland. Journal of Surgical Case Reports, 2021(11), rjab504. https://doi.org/10.1093/jscr/rjab504
51. The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate—PubMed. (s. f.). Recuperado 26 de octubre de 2022, de https://pubmed.ncbi.nlm.nih.gov/31487219/
52. Van Cauwenbergh, O., Di Serafino, A., Tytgat, J., & Soubry, A. (2020). Transgenerational epigenetic effects from male exposure to endocrine-disrupting compounds: A systematic review on research in mammals. Clinical Epigenetics, 12(1), 65. https://doi.org/10.1186/s13148-020-00845-1
53. Watts, E. L., Goldacre, R., Key, T. J., Allen, N. E., Travis, R. C., & Perez‐Cornago, A. (2020). Hormone‐related diseases and prostate cancer: An English national record linkage study. International Journal of Cancer, 147(3), 803-810. https://doi.org/10.1002/ijc.32808
54. Wu, W., Wang, L., Spetsieris, N., Boukovala, M., Efstathiou, E., Brössner, C., Warner, M., & Gustafsson, J.-A. (2021). Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proceedings of the National Academy of Sciences, 118(13), e2011269118. https://doi.org/10.1073/pnas.2011269118
55. Wu, Y., Ding, Y., Cao, Q. F., Qian, S. B., Wang, C., Duan, H. Q., Gu, J., & Shen, H. B. (2020). The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia. World Journal of Urology, 38(11), 2923-2931. https://doi.org/10.1007/s00345-020-03084-4
56. Xia, B., Zhao, S., Chen, Z., Chen, C., Liu, T., Yang, F., & Yan, Y. (2020). The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume. The Prostate, 80(6), 481-490. https://doi.org/10.1002/pros.23962
57. Xin, C., Fan, H., Xie, J., Hu, J., Sun, X., & Liu, Q. (2022). Impact of Diabetes Mellitus on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: A Meta-Analysis. Frontiers in Endocrinology, 12, 741748. https://doi.org/10.3389/fendo.2021.741748
58. Xiong, Y., Zhang, Y.-C., Jin, T., Qin, F., & Yuan, J.-H. (2021). Depressive males have higher odds of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A retrospective cohort study based on propensity score matching. Asian Journal of Andrology, 23(6), 633. https://doi.org/10.4103/aja.aja_12_21
59. Zhang, P., Qian, B., Liu, Z., Wang, D., Lv, F., Xing, Y., & Xiao, Y. (2021). Identification of novel biomarkers of prostate cancer through integrated analysis. Translational Andrology and Urology, 10(8), 3239-3254. https://doi.org/10.21037/tau-21-401
60. Zhou, Y., Xie, S., Zheng, R., Dai, Q., Xu, Z., Zuo, W., Ding, J., & Zhang, Y. (2020). Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. Journal of International Medical Research, 48(6), 030006052092454. https://doi.org/10.1177/0300060520924548
Publicado
2022-11-19
Cómo citar
Beatriz Alexandra Gaibor González, & José Clímaco Cañarte Vélez. (2022). Antígeno prostático específico y factores de riesgo asociados a anomalías prostáticas. Revista Científica FIPCAEC (Fomento De La investigación Y publicación científico-técnica multidisciplinaria). ISSN : 2588-090X . Polo De Capacitación, Investigación Y Publicación (POCAIP), 7(4), 397-428. Recuperado a partir de https://fipcaec.com/index.php/fipcaec/article/view/641
Sección
Artículos de Investigación
